Navigation Links
Canada launches first gene therapy trial for Fabry disease
Date:1/24/2013

infusion of medication. Although the infusions help manage his illness, they aren't a cure and they're something he has to organize his life around.

Armstrong, who was diagnosed in 2007, has experienced a thickening in one of the walls of his heart due to Fabry disease. "Even if the research meant that I had to come in once every six months for Enzyme Replacement Therapy, instead of every two weeks, then it would still be another step toward living a normal life," Armstrong says.

In the current pre-clinical phase of the study, researchers hope to demonstrate Armstrong's corrected stem cells are able to provide a source of enzyme in a specially adapted mouse that has Fabry disease. After this is accomplished, the second phase will repeat the experiment using a new donor with all the checks and balances needed for a human trial. Once the pre-clinical experimental results have satisfied the regulatory requirements of Health Canada, the team aims to treat the first human Fabry disease patient, which they estimate will be within two years.


'/>"/>
Contact: Gregory Harris
gregory.harris@albertahealthservices.ca
403-619-3108
Alberta Health Services
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Disease-carrying colonizers on the move: Predicting the spread of ticks across Canada
2. Ducks Unlimited Canada and Canadian Light Source partnership to shed light on wetlands
3. Potent human toxins prevalent in Canadas freshwaters
4. Meet Xenoceratops: Canadas newest horned dinosaur
5. USAs ancient hurricane belt and the US-Canada equator
6. Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries
7. LABS, Inc. Launches Suite of Next-Generation Test Offerings; Focuses on Expanding Complex Biologic Testing Portfolio in 2012
8. Elsevier launches new journal Algal Research
9. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
10. Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes
11. WanderID Launches Breakthrough ID Product for Children, Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... By discovering the new mechanism by which estrogen suppresses ... revealed a potential new approach toward treating certain liver ... and colleagues believe they are changing long-held views in ... issue of the journal Science Signaling . , ... years has been that only receptors located in the ...
(Date:5/23/2013)... Some prostate cancer patients unnecessarily undergo surgery or ... differences between slow-growing and aggressive forms of the ... Johns Hopkins Medical Institutes are developing technology that ... opt for relatively mild treatments or take drastic ... Anant Madabhushi, an associate professor of biomedical engineering ...
(Date:5/23/2013)... world are billions of animal and plant specimens from ... all stacked, stored and preserved in jars and collection ... critical to understanding how the Earth,s biodiversity is changing ... if only the information were easily accessible. , A ... of a team from the University of Colorado Boulder, ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... been shed on proteorhodopsin, the light-sensitive protein found in ... of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and ... when the ability to respire oxygen is impaired, bacterium ... carry out vital life processes. , ...
... onset of type 1 diabetes in mice prone to ... on the surface of immune T-cells. According to the ... January issue of the journal Diabetes, have significant implications ... More than 700,000 Americans have type 1 diabetes, an ...
... soon be able to cultivate new tomato varieties without ... This is the conclusion of the STW-sponsored thesis by ... to earn his doctorate on 3 April 2007. Finkers ... resistant to grey mould. The leading company De Ruiter ...
Cached Biology News:Shedding new light on proteorhodopsin 2Shedding new light on proteorhodopsin 3Antibody therapy prevents type 1 diabetes in mice 2Research on grey mould offers possible breakthrough in tomato cultivation 2
(Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan Racing ... cord blood stem cell banking and therapeutics, announced today ... No. 16 Acorn Stairlifts Indy car driven by ... remainder of the IZOD IndyCar 2013 season.   ... work to support awareness of umbilical cord blood banking ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... May 23, 2013 The New Jersey ... industries, Black Data Processing Associates (BDPA), is hosting its ... 8, 2013. This all-day event will encourage students and ... the ins and outs from many of the industries’ ... at the New Jersey Institute of Technology, the event ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2
... ... 2009 and is now serving 7 of the Top 10 pharmaceutical and 3 of the ... ... 2009 -- OpenQ, a leading provider of technology and information solutions for the life sciences ...
... , , WAYNE, Pa., July 17 ... ENCO ), a full service multinational clinical research organization ... clinical trials and patient registries to many of the ... completed the previously announced sale of the Company,s U.S. ...
... , HOPKINTON, Mass., July 16 ... a conference call discussing the company,s second quarter 2009 financial results ... President and Chief Executive Officer and Peter McAree, Chief Financial Officer, ... and the company,s outlook for the future. , ...
Cached Biology Technology:OpenQ Posts a 200% Revenue Growth in the First Half of 2009 2Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 2Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 3Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 4Caliper Life Sciences' Second Quarter 2009 Financial Results Conference Call Notice 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Goat polyclonal to Glucose Dehydrogenase ( Abpromise for all tested applications). Antigen: Glucose Dehydrogenase (Bacillus species)...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Biology Products: